Examining Novel Fentalogs: Pharmacological Characteristics and Reversibility

检查新型 Fentalogs:药理学特征和可逆性

基本信息

项目摘要

Opioid analgesics, such as morphine and hydrocodone, are widely used for the treatment of moderate to severe pain but are also widely misused and abused. Opioid-related overdoses account for almost half of all drug overdose deaths in the United States and cause more preventable deaths every year than car crashes. Fentanyl, a highly potent mu opioid receptor (MOR) agonist, and its analogues (fentalogs) are increasingly found in drug samples from search and seizure by law enforcement and are thought to contribute to the drastic increase in opioid-induced overdose deaths since 2016. In fact, the number of deaths and drug seizures involving fentalogs is likely an underestimate, as the rapid rate at which new fentalogs are synthesized makes it difficult for law enforcement and forensic specialists to keep up. As many of these compounds are novel analogs, very little is known about their basic pharmacology in terms of receptor affinity or activity at the opioid receptors. The objective of this proposal is to evaluate novel fentalogs, many of which have been identified in illicit samples, in terms of binding affinity and receptor function at the three classical opioid receptors: MOR, the delta opioid receptor (DOR), and the kappa opioid receptor (KOR). This will be accomplished using standard competitive radioactive ligand binding and G protein turnover assays. The ability of a standard rescue therapy, naloxone (trade name Evzio or Narcan), to reverse the agonist activity of the most potent and efficacious fentalogs will also be examined; real time cAMP accumulation will be used to determine agonist function and reversal by antagonists, such as naloxone. The overarching hypothesis is that many of these novel fentalogs are more potent and efficacious than traditional opioid agonists and that standard treatments for opioid overdose may be insufficient when fentalogs are involved. Overall, this project will characterize the in vitro pharmacological properties of novel fentalogs found in street drugs and has the potential to inform best practices for preventing opioid overdose and related deaths.
阿片类镇痛剂,如吗啡和氢可酮,被广泛用于治疗 可用于中度至重度疼痛,但也被广泛误用和滥用。阿片类药物相关 服药过量占美国所有服药过量死亡的近一半, 每年造成的可预防的死亡人数比车祸还多。芬太尼,一种高效的 MU阿片受体(MOR)激动剂及其类似物(芬太洛)的发现越来越多 在被执法部门搜查和扣押的毒品样本中被认为 这是自2016年以来阿片类药物过量死亡大幅增加的原因之一。事实上, 与芬太洛有关的死亡和缉获毒品的数量可能被低估了,因为 合成新芬太尼的速度太快,这让法律很难 执法和法医专家要跟上。因为这些化合物中的许多都是新的 类似物,就受体亲和力而言,人们对其基本药理知之甚少 或阿片受体的活动。这项建议的目的是评价小说 芬太罗,其中许多已在非法样本中发现,就结合亲和力而言 受体在三个经典的阿片受体上发挥作用:MOR,增量阿片受体 受体(DOR)和kappa阿片受体(KOR)。这将通过以下方式完成 标准竞争性放射性配基结合试验和G蛋白周转试验。一种能力 标准的抢救疗法,纳洛酮(商标是Evzio或Narcan),以逆转 最有效和最有效的芬太洛的激动剂活性也将被检查;真实 时间cAMP积累将被用来确定激动剂的功能和逆转 拮抗剂,如纳洛酮。最重要的假设是,这些小说中的许多 芬太洛比传统的阿片激动剂更有效,而且 当涉及芬太洛时,阿片类药物过量的标准治疗可能是不够的。 总体而言,本项目将表征新药的体外药理特性 在街头毒品中发现的芬太罗,并有可能成为 预防阿片类药物过量和相关死亡。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jessica Priya Anand其他文献

Jessica Priya Anand的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jessica Priya Anand', 18)}}的其他基金

Development of Long Lasting Stable Fentanyl Antagonist to Reverse Opioid Overdose
开发长效稳定芬太尼拮抗剂以逆转阿片类药物过量
  • 批准号:
    10197869
  • 财政年份:
    2020
  • 资助金额:
    $ 7.8万
  • 项目类别:
Development of Long Lasting Stable Fentanyl Antagonist to Reverse Opioid Overdose
开发长效稳定芬太尼拮抗剂以逆转阿片类药物过量
  • 批准号:
    10041480
  • 财政年份:
    2020
  • 资助金额:
    $ 7.8万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Novel PPAR-gamma agonist selectively activate the ligand binding domain of PPAR-gamma and improve pathology and memory deficits in a 3xTg-Ad mouse model.
新型 PPAR-gamma 激动剂选择性激活 PPAR-gamma 的配体结合域,改善 3xTg-Ad 小鼠模型的病理和记忆缺陷。
  • 批准号:
    8890576
  • 财政年份:
    2015
  • 资助金额:
    $ 7.8万
  • 项目类别:
Atomic force microscopy study of structural and functional changes in membrane proteins upon agonist and antagonist binding
激动剂和拮抗剂结合后膜蛋白结构和功能变化的原子力显微镜研究
  • 批准号:
    BB/M503113/1
  • 财政年份:
    2014
  • 资助金额:
    $ 7.8万
  • 项目类别:
    Training Grant
Agonist & Antagonist Activity and Binding on the TMD of hT1R3
激动剂
  • 批准号:
    7915254
  • 财政年份:
    2009
  • 资助金额:
    $ 7.8万
  • 项目类别:
Imaging Dopamine D2 Agonist Binding Sites in Cocaine Dependence with [11C]NPA
使用 [11C]NPA 对可卡因依赖中的多巴胺 D2 激动剂结合位点进行成像
  • 批准号:
    7782808
  • 财政年份:
    2009
  • 资助金额:
    $ 7.8万
  • 项目类别:
Imaging Dopamine D2 Agonist Binding Sites in Cocaine Dependence with [11C]NPA
使用 [11C]NPA 对可卡因依赖中的多巴胺 D2 激动剂结合位点进行成像
  • 批准号:
    7587737
  • 财政年份:
    2009
  • 资助金额:
    $ 7.8万
  • 项目类别:
Agonist & Antagonist Activity and Binding on the TMD of hT1R3
激动剂
  • 批准号:
    7725379
  • 财政年份:
    2009
  • 资助金额:
    $ 7.8万
  • 项目类别:
CONFORMATIONAL CHANGES AND MODE OF BINDING OF AGONIST TO ESTROGEN RECEPTOR
激动剂与雌激素受体的构象变化和结合方式
  • 批准号:
    7724014
  • 财政年份:
    2008
  • 资助金额:
    $ 7.8万
  • 项目类别:
Molecular determinants of melanocortin 4 receptor for selective agonist binding
黑皮质素 4 受体选择性激动剂结合的分子决定因素
  • 批准号:
    7669106
  • 财政年份:
    2008
  • 资助金额:
    $ 7.8万
  • 项目类别:
Agonist & Antagonist Activity and Binding on the TMD of hT1R3
激动剂
  • 批准号:
    7706667
  • 财政年份:
    2008
  • 资助金额:
    $ 7.8万
  • 项目类别:
Molecular recognition of barbiturate enantiomers in agonist binding site of nicotinic acetylcholine receptor
烟碱乙酰胆碱受体激动剂结合位点巴比妥酸盐对映体的分子识别
  • 批准号:
    19791062
  • 财政年份:
    2007
  • 资助金额:
    $ 7.8万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了